Navigation Links
ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
Date:4/1/2008

LEUVEN, Belgium, April 1 /PRNewswire-FirstCall/ --

- Trial Results Expected Mid-2008

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, today announces that it has completed patient enrolment for its Phase IIb MIVI III trial in the United States. This study is designed to evaluate the safety and efficacy of Microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection).

A vitrectomy is a surgical procedure carried out in the treatment of many back of the eye diseases such as retinal detachment, diabectic vitreous hemorrhage and macular hole. Vitrectomy is used to induce a posterior vitreous detachment (PVD) which involves removing the vitreous via suction. Microplasmin is a proteolytic enzyme that cleaves important molecules which link the vitreous to the retina and therefore has the potential to facilitate vitrectomy and induce PVD without the risks inherent in detachment by surgical intervention.

MIVI III is a Phase IIb, randomized, double-masked, placebo-controlled, dose-ranging trial evaluating three doses of Microplasmin (25, 75 and 125 μg) versus placebo in 120 patients scheduled for vitrectomy. The trial is taking place across 19 sites throughout the United States and is assessing the safety and efficacy of Microplasmin intravitreal injection 7 days prior to vitrectomy. Top-line, unmasked results of this trial are expected in June 2008.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on today's announcement, said: "We are very pleased to have completed enrolment in our lead program. Microplasmin has the potential to significantly change the way we treat back of the eye diseases and this study will bring us a step closer to realising this potential. Due to encouraging safety and efficacy results obtained from both the MIVI I and MIVI II Traction Phase II trials which were conducted in Europe, we are confident that
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
2. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
3. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
4. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
5. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
6. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
7. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
8. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
9. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
10. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
11. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... MUMBAI , July 2, 2015 ... equity stake in ZAO "Biocom" in Russia ... foray into the Russian pharmaceutical market which recorded RUB 765 ... 10 pharmaceutical markets in the world in 2014 (IMS Health). ... growth and expected to continue with this trend, projecting ...
(Date:7/2/2015)... 2, 2015 The report "Silage ... Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), ... 2020", Silage Inoculants & Enzymes Market is expected to ... 4.0% from 2015 to 2020. Browse ... through 194 P ages and an ...
(Date:7/2/2015)... 2015 BGI gab heute bekannt, ... vom American College of Pathologists (CAP) akkreditiert ... erste klinische Next-Generation-Sequencing Labor, das in ... und somit die höchsten Standards an klinischer ... FDA - 21 CFR Part 11 konformen ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... BROWNE, MORGAN FREEMAN, SAMUEL L. JACKSON, GEORGE LOPEZ, ... Oct. 24 On Thursday, November 15, 2007,Artists for a ... benefit, at The Wiltern in Los Angeles. The evening combines,the ... -- from the personal,to the global -- and make a ...
... Support Preclinical Development of Intradigm,s ICS-283, ... Corporation, a,leading developer of targeted, systemic RNA ... demonstrated the company,s,TargeTran(TM) delivery system is capable ... small interfering RNAs (siRNAs) that suppress,tumor-induced angiogenesis ...
Cached Medicine Technology:Artists for a New South Africa Will be 'Shaking The Blues' at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb' Mo', Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles 2Artists for a New South Africa Will be 'Shaking The Blues' at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb' Mo', Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles 3Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 2Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 3
(Date:7/2/2015)... ... July 02, 2015 , ... ... Krishnareddy, M.D., to the orthopedic and spine surgery team at their Anaheim clinic. ... bursitis, and tendonitis. Along with the spine and spine surgery, Dr. Krishnareddy also ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ... procedures and executing them with care and precision. There is an art and ... has had the honor of successfully reshaping the facial features and lives of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough technologies are now available ... Lev Kalika, founder of New York Dynamic Neuromuscular Rehabilitation & Physical Therapy ... treatment of back, hip, knee and shoulder pain as well as sports injury ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... Research (CVR) recently received nearly $4 million through five federal grants to ... vaccines and therapies against the deadly diseases. , The research will be ...
(Date:7/2/2015)... ... July 02, 2015 , ... eHuman Digital ... new release of their flagship product, 3D Tooth Atlas, version 7.6. This release ... and new tutorial videos. This latest release of the 3D Tooth Atlas offers ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:eHuman Digital Anatomy Releases 3D Tooth Atlas version 7.6 2
... to lead BCBSIL,s sales and,marketing, CHICAGO, May ... senior vice president, Local and Consumer Markets, for,Blue ... his new role, Freer,will oversee small, mid-market, and ... as well as manage HMO Illinois. Freer also,will ...
... teach low-income adults about healthy food choices is a ... benefits achieved, reports a cost-effectiveness study in the May/June ... http://www.jneb.org/ ). , Led by Jamie Dollahite, Ph.D., R.D., ... evaluations to assess the costs versus benefits of the ...
... 13 Medivation, Inc.,(Nasdaq: MDVN ) today announced that David ... conferences., -- Rodman & Renshaw 5th Annual Global Healthcare ... p.m. local time at Le Meridien Beach Plaza Hotel in ... Generic Pharmaceuticals Conference on Wednesday, May 28 ...
... May 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... of pharmaceutical, medicinal and diagnostic products in China,today ... at 5:00 p.m. Eastern,Time on May 15, 2008 ... Joining Mr. Yan-qing Liu, Chairman, CEO and ...
... The Quantum Group,(Amex: QGP ) today announced ... has expanded its relationship with one of its ... of its Community Health,System. This expanded relationship will ... Medicaid patients. The contract will initially cover,South Florida, ...
... Fla., May 13 A complete review of ... a multi-disciplinary and,collaborative approach to weight loss, according ... The use of several proven,weight management strategies in ... the greatest likelihood of success., NBC,s hit ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Illinois Names New Vice President, Local and Consumer Markets 2Health News:Expanded food and nutrition program shows $10 benefit for each $1 spent 2Health News:Medivation Announces Participation in Upcoming Conferences 2Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:The Quantum Group Executes First Medicaid Service Contract with HMO 2Health News:The Quantum Group Executes First Medicaid Service Contract with HMO 3Health News:Research Converging in Favor of New Approach to U.S. Weight Problem 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: